

**Hard to Treat Diseases (HTDS) – (PINK SHEETS FILING) Management Reply To Shareholders FAQ on Various Past News Releases and General Corporate Update**

SHENZHEN, October 1, 2009 - HTDS [www.htdsmedical.com](http://www.htdsmedical.com) (HTDS) The issuer's China based operating subsidiary Mellow Hope and Serbia operating Subsidiary Slavica Bio Chem are providing this update to its shareholders and followers. This update may not be news worthy to release however the management sees this as a great way to bring its followers and shareholders up to date with various events and pending transactions, and to provide an update on past news releases. Any grammatical errors are due to the actual verbatim translations from the China officers and Directors.

**FAQ:**

\* What is the status on removing the caveat emptor classification of this stock?

The company believes that there is a naked short interest in the stock and the company has retained counsel to investigate this matter and possible market manipulation by short sellers. In this connection, the Company has received numerous allegations and complaints from shareholders. In addition, the company has been the victim of anonymous “stock bashing” and a campaign of negative publicity, a smear campaign. In fact, there is a lawsuit in progress on some of these issues. Therefore, with regard to this question the company complied with Pink Sheets Adequate Disclosure as per its Filings namely

<a href="#">Attorney Letter with Respect to Current Information</a> - HTDS Legal Opinion	Jun 30, 2009	Sept 21, 2009
<a href="#">Initial Company Information and Disclosure Statement</a> - Adequate Info amended	Jun 30, 2009	Sept 21, 2009

The company has received this reply to its request to have the Skull and Bones icon removed:

[SIC] “Based on the information provided in the letter written by Mr. Essman and dated September 9, 2009, Pink OTC Markets has determined to keep the Caveat Emptor designation for Hard to Treat Diseases in place for the time being. The Caveat Emptor designation is intended as a warning to investors and as Mr. Essman stated, the Company is currently investigating possible market manipulation by short sellers and has itself received numerous investor complaints, each of which merits caution on the part of potential investors.”

The company disagrees with this decision and sees this as an aid to short position and not something that will rain the short sellers. The company is currently appealing this decision and is also in discussions with other USA and Canadian based lawyers to see what legal remedies may be available to the company.

\* What is the status on the intellectual property rights claim that HTDS is attempting to recover?

The company is in negotiations with its IP claim and with those it believed it usurped its IP rights. An update should be forthcoming on this matter shortly and initial progress does look positive.

\* Is HTDS still entertaining the unsolicited proposals that were received in their rights in cancer and anti-aging projects? Is so, is the scheduled October 7 to October 11 date for review still applicable? How does this all fit in HTDS?

Yes HTDS management is in serious discussions with a Canadian Pharmaceutical company for the sale of these IP rights. These solutions belong to the IBISS Group and the Government of Serbia. HTDS has IP rights to these projects primarily because its directors namely Dr.Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer and Prof Mirjana Stojilkovic, Director, New Projects, Chief Scientist. The Canadian Pharmaceutical company has expressed serious interest in the cancer project while the anti aging project is still being made available to others. The October 7 to October 11 date has been moved to October 20 to 24 at which time meetings with IBISS and Serbia Government will take place to move this project further. HTDS management is mindful that these cancer and anti aging projects while they have a lot of potential are still in developmental and research stage, which will require capital to fund its research to its fruition. HTDS management is not prepared to dilute its security to fund the research however sees an opportunity in selling a majority of its stake of the cancer project to the Canadian Pharmaceutical company so that they may fund it. If this cancer research turns out to be positive then HTDS will still benefit through capital appreciation of the Canadian company stock it will take. If the research turns out negative HTDS management would have spared HTDS the unnecessary dilution. The company wants to see the massive short position covered.

\* Is the company making any progress towards locating and taking legal action against the stock manipulators that were reported to them via the posted reward program?

Very much so. Several posters have been identified and some clearly use more than one screen name (They are one of the same) see link of our IR company [http://www.minamargroup.com/stock\\_bashers.php](http://www.minamargroup.com/stock_bashers.php) We have identified many more which will be posted shortly. Some we believe are brokers and or involved in the industry while many appear not even to be shareholders according to the NOBO lists of the company.

\* It is our understanding that the company has already won the lawsuit against Investor Hub, so what is the status of collection efforts on the judgement in that case?

Judgement will be entered soon and exported to Florida. The company sees good prospects in this regard although one of the defendants may not have the required funds to settle the claim and has other issues with USA authorities.; which may be the reason it ceased defending the main action in Canada. The company believes they are just one of many victims of these individuals actions.

55.6055 Foreign defamation judgment.--

(1) For the purposes of rendering declaratory relief with respect to a person's liability for a foreign defamation judgment and determining whether the foreign defamation judgment should be deemed nonrecognizable under s. 55.605, the courts of this state have personal jurisdiction over any person who obtains a judgment in a defamation proceeding outside the United States against any person who:

(a) Is a resident of this state;

(b) Is a person or entity amenable to the jurisdiction of this state;

(c) Has assets in this state; or

(d) May have to take action in this state to comply with the judgment.

(2) This section applies to judgments rendered in defamation proceedings outside the United States before, on, or after July 1, 2009.

\* By definition, a "tender" is an "offer"; On the Mellow Hope web site it is stated that "In August of 2009, Mellow Hope will participate in a tender for supplying 6 million doses of H1N1 Flu Vaccine to Chile and another tender for supplying 1 million doses of H1N1 flu vaccine to Thailand." So, have either of these two offers been contractually accepted?

Mellow Hope is optimistic on both Chile deals and its confidence is very high, that Mellow Hope will finalize with Chile government on those transactions very soon.

\* What is the status in regards to providing the videos of the Mellow Hope facilities that were promised to the investors?

The video and images are being worked on now. There are many proprietary systems used and the company is having each image reviewed by its legal counsel prior to general release

\* In a press release dated September 14, 2009 it is clearly stated "At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) <http://eng.sfda.gov.cn/eng>. Production will be started shortly." In the follow up press release dated

September 17 it is stated that "The H1N1 Vaccine manufacturing license will be granted soon." What is the status on the issue of the vaccine manufacturing license?

The H1N1 clinical trials through its close partners in China have been approved; the manufacture license through close partner was granted on September 24, 2009 to its close manufacturing partner: Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd ( Mellowhope is its exclusive agent for international marketing and sales)

To receive regular updates on HTDS please sign up or opt in with your email address at this link <http://www.minamargroup.com/updates/>

### Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [medicalinfo@htdsmedical.com](mailto:medicalinfo@htdsmedical.com); For any corporate matters, please contact [www.minamargroup.com/helpdesk](http://www.minamargroup.com/helpdesk)

Investor Relations Department, (302) 357-9915 (IR), 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A), Corporate Matters, [www.minamargroup.com](http://www.minamargroup.com) (M&A), [www.minamargroup.net](http://www.minamargroup.net) (IR)